Loading clinical trials...
Loading clinical trials...
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
Conditions
Interventions
TTX-030, budigalimab and mFOLFOX6
TTX-030, budigalimab and docetaxel
+6 more
Locations
32
United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
City of Hope Medical Center Clinical Trials Office
Duarte, California, United States
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
UCLA Hematology/Oncology
Los Angeles, California, United States
Chao Family Comprehensive CC, UCI
Orange, California, United States
Start Date
March 30, 2020
Primary Completion Date
November 30, 2022
Completion Date
March 27, 2024
Last Updated
July 29, 2025
NCT03594422
NCT05223608
NCT06625775
NCT06051695
NCT06265727
NCT04665206
Lead Sponsor
Trishula Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions